Developing new drugs for cancers driven by RAS-MAPK pathways
Official title: Molecular Glues to Target RAS-MAPK Driven Cancers
Funded at Sloan-Kettering Inst Can Research · NIH-11015050 · Data updated 2026-11-12
This study is working on new types of cancer drugs that aim to be safer and more effective by targeting specific parts of a key pathway involved in cancer growth, which could help patients with different cancers, including colorectal cancer, and reduce side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 1, 2023 |
| Project end | February 29, 2028 |
| Funding year | 2025 |
| Award (this year) | $479,518 |
| NIH project number | 5R01CA227636-09 |
| Project ID | NIH-11015050 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with RAS-MAPK driven cancers, such as those with mutations in KRAS or BRAF.
✕Less likely to help
Patients with cancers not driven by RAS-MAPK pathways may not benefit from this research.
What this research studies
This research focuses on creating a new class of drugs that target specific binding sites in the RAS-MAPK signaling pathway, which is crucial in many cancers. By avoiding traditional drug design that targets active sites, the approach aims to enhance drug selectivity and reduce side effects, potentially overcoming issues like drug resistance. The research involves detailed structural studies of key proteins involved in cancer, which will guide the development of safer and more effective therapies for patients. This innovative strategy could lead to breakthroughs in treating various cancers, including colorectal cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer cancer treatments with fewer side effects for patients.
How similar studies have gone: Other research has shown promise in targeting similar pathways, but this approach is innovative and aims to address limitations of existing therapies.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Dar, Arvin — Sloan-Kettering Inst Can Research
- Study coordinator: Dar, Arvin
Related research
Other NIH-funded projects on the same topics.
-
Understand how skeletal muscle nuclei specialize and arrange themselves for proper muscle function
A study to uncover how the hundreds of nuclei in skeletal muscle fibers acquire different roles and positions to keep muscles strong and healthy.
-
Genomic profiling and outcomes of cancers in World Trade Center-exposed survivors and responders
This project looks at the genetic makeup and real-world cancer outcomes in people exposed to the World Trade Center disaster to understand how their cancers behave and respond to treatments.
-
Meaning-Centered Psychotherapy for Mexican Patients with Advanced Cancer
A cancer center in Mexico will test a culturally adapted therapy to help Mexican patients with advanced cancer find meaning, peace, and purpose at the end of life.
-
High-specificity genome-scale cell-surface proteomics to find tumor targets
A cancer research project is trying to map all the proteins on the surface of ultra-rare sarcoma cells to find safe, targeted ways to treat them.
-
Priorities for testing and choosing combination therapies in rhabdoid tumors to guide clinical trials
A coordinated, multi-site effort will rigorously test promising drug combinations in rhabdoid tumors to identify the most promising options for future patient trials.
-
ecDNA in Cancer: Understanding and targeting circular DNA that drives tumor growth
A cancer-focused project to understand how extrachromosomal DNA helps tumors grow and resist treatment, and to develop new ways to target these mechanisms.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.